BiotechTube

SHR-1314

Phase 1UNKNOWN
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bioequivalence

Conditions

Bioequivalence

Trial Timeline

Aug 20, 2020 → Mar 30, 2021

NCT ID
NCT04527484

About SHR-1314

SHR-1314 is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Bioequivalence. The current trial status is unknown. This product is registered under clinical trial identifier NCT04527484. Target conditions include Bioequivalence.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (4)

NCT IDPhaseStatus
NCT04527484Phase 1UNKNOWN
NCT04326881Phase 1UNKNOWN
NCT03710681Phase 1UNKNOWN
NCT03704428Phase 1Completed

Competing Products

20 competing products in Bioequivalence

See all competitors
ProductCompanyStageHype Score
Bupropion HCl MR tablets 300mgAlembic PharmaceuticalsPhase 1
32
Fingolimod 0.5 mg capsules- Test drugAlembic PharmaceuticalsPhase 1
32
Lamotrigine ER tablet 50mgAlembic PharmaceuticalsPhase 1
32
Sonelokimab + SonelokimabMoonLake ImmunotherapeuticsPhase 1
28
GP30101 + Prezista® + GP30101 + Prezista®GEROPHARMPre-clinical
15
Metformin + Glucophage® + Metformin + Glucophage®GEROPHARMPhase 1
25
Metformine + Glucophage® Long + Metformin + Glucophage® LongGEROPHARMPhase 1
25
Humulin® Regular + Rinsulin® RGEROPHARMPre-clinical
15
Bosentan 125 mg + Tracleer 125Mg TabletGEROPHARMPhase 1
25
Rinsulin® mix 30/70 + Humulin® M3GEROPHARMPre-clinical
15
Memantinol tablets, 20 mg + Akatinol Memantine® tablets, 20 mgGEROPHARMPhase 1
25
Clocortolone PivalateSun PharmaceuticalPhase 1
33
Oxymetazoline hydrochloride Cream, 1% + Rhofade™ (oxymetazoline) cream, 1% + PlaceboSun PharmaceuticalPhase 1
33
Tablet paracetamol, guaifenesin and phenylephrine HCL + Vicks Active SymptoMax Plus powder for oral solutionJohnson & JohnsonPhase 1
33
Onglyza (saxagliptin) + Diabex + 5-mg saxagliptin/1000 mg metformin + Diabex + 5-mg saxagliptin/500 mg metforminAstraZenecaPhase 1
33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
33
OmeprazoleAstraZenecaPhase 1
33
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)AstraZenecaPhase 1
33
D961S + Esomeprazole + Buffered acetylsalicylic acidAstraZenecaPhase 1
33
Treatment A: Acalabrutinib tablet + Treatment B: Acalabrutinib capsuleAstraZenecaPhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85